Major histocompatibility complex, class I, B mRNA (HLA-B mRNA)

Major histocompatibility complex, class I, B (HLA-B) mRNA is the transcript responsible for the synthesis of the HLA-B heavy chain, a critical component of the human immune system's antigen presentation machinery. The HLA-B protein, once translated and folded with beta-2 microglobulin, presents endogenous peptides to CD8+ cytotoxic T cells, facilitating the detection of viral infections and transformed cells (UniProt P01889). The HLA-B gene is the most polymorphic locus in the human genome, and specific mRNA variants are highly associated with susceptibility to autoimmune disorders, such as Ankylosing Spondylitis (HLA-B*27), and severe cutaneous adverse reactions (SCARs) to various medications (NCBI Gene: 3106). For example, the presence of HLA-B*57:01 mRNA/protein is a definitive contraindication for the use of the antiretroviral drug Abacavir due to the risk of life-threatening hypersensitivity (FDA Label). While most current clinical focus is on HLA-B as a pharmacogenetic biomarker, experimental therapies using RNA interference (RNAi) or antisense oligonucleotides (ASOs) are being developed to selectively silence pathogenic HLA-B mRNA alleles (PubMed: 15634878). These nucleic acid-based approaches represent a potential precision medicine strategy to treat HLA-linked diseases by reducing the expression of specific, disease-associated transcripts.

Other names

MHC class I antigen B mRNAHLA-B transcriptHuman leukocyte antigen B mRNAASB-LDR

RNA interference (siRNA-mediated degradation), antisense oligonucleotide-mediated inhibition, or allele-specific silencing to prevent the translation of pathogenic MHC class I proteins.